Minocycline for Chronic Autoimmune Uveitis

Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.

Changes in Implicit Time and Amplitude of Photopic and Scotopic Responses measured by Electroretinogram (ERG) Testing

Number of ocular and non-ocular adverse events Number of ocular and non-ocular adverse events Number of ocular and non-ocular adverse events Number of ocular and non-ocular adverse events Number of Ocular and Non-ocular Adverse Events

Inclusion Criteria: Participant diagnosed of autoimmune diseases with visual function damage (decrease of BCVA, loss of retinal structure) Participant aged from 18-60 years old. Participant that signed the informed consent document and is able to complete the following visits. Exclusion Criteria: Participant is allergy to minocycline or tetracyclines. Participant has no contraindications of minocycline or tetracyclines. Participant has an abnormal function of liver, heart, kidney and thyroid. Participant is using glucocorticoids, immunosuppressants or biologics. Female that is pregnant, breast-feeding or planning to become pregnant. Participant that is currently using other medications for other diseases.